The objective of this study was to compare the performance of metal oxide semiconductor field-effect transistor
(MOSFET) technology dosemeters with thermoluminescent dosemeters (TLDs) (TLD 100; Thermo Fisher Scientific, Waltham, MA) in
the maxillofacial area.
Organ and effective dose measurements were performed using 40 TLD and 20 MOSFET
dosemeters that were alternately placed in 20 different locations in 1 anthropomorphic RANDO® head phantom (the Phantom Laboratory,
Salem, NY). The phantom was exposed to four different CBCT default maxillofacial protocols using small (4 × 5 cm) to full
face (20 × 17 cm) fields of view (FOVs).
The TLD effective doses ranged between 7.0 and 158.0 µSv and
the MOSFET doses between 6.1 and 175.0 µSv. The MOSFET and TLD effective doses acquired using four different (FOV) protocols
were as follows: face maxillofacial (FOV 20 × 17 cm) (MOSFET, 83.4 µSv; TLD, 87.6 µSv; −5%); teeth, upper jaw (FOV, 8.5 × 5.0 cm)
(MOSFET, 6.1 µSv; TLD, 7.0 µSv; −14%); tooth, mandible and left molar (FOV, 4 × 5 cm) (MOSFET, 10.3 µSv; TLD, 12.3 µSv; −16%)
and teeth, both jaws (FOV, 10 × 10 cm) (MOSFET, 175 µSv; TLD, 158 µSv; +11%). The largest variation in organ and effective
dose was recorded in the small FOV protocols.
Taking into account the uncertainties of both measurement
methods and the results of the statistical analysis, the effective doses acquired using MOSFET dosemeters were found to be
in good agreement with those obtained using TLD dosemeters. The MOSFET dosemeters constitute a feasible alternative for TLDs
for the effective dose assessment of CBCT devices in the maxillofacial region.